Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?
Background
This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.
Background
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
Background
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
